Highmark Approves Coverage for Plus Therapeutics’ CNSide CSF Assay, Expanding Access to 75 Million Lives Nationwide

Plus Therapeutics has announced that Highmark, one of the largest health insurance providers in the United States, has agreed to provide coverage for CNSide® CSF Assay. This decision expands reimbursement access for the diagnostic test to approximately 75 million covered lives nationwide. The CNSide® CSF Assay is designed to analyze cerebrospinal fluid (CSF) and assist in diagnosing and monitoring central nervous system cancers.

The inclusion of Highmark’s coverage marks a significant milestone for Plus Therapeutics, as it broadens accessibility to its diagnostic tool across a wider patient population. Highmark joins other insurers who have already approved reimbursement for CNSide®, further solidifying its availability within the healthcare system. This development reflects ongoing efforts by Plus Therapeutics to secure partnerships with major payers and enhance patient access to innovative diagnostic solutions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI